摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(2-乙酰基-4-溴苯氧基)乙酸 | 34849-51-9

中文名称
2-(2-乙酰基-4-溴苯氧基)乙酸
中文别名
——
英文名称
(2-acetyl-4-bromophenoxy)acetic acid
英文别名
[(2-acetyl-4-bromophenyl)oxy]acetic acid;2-(2-acetyl-4-bromophenoxy)acetic acid
2-(2-乙酰基-4-溴苯氧基)乙酸化学式
CAS
34849-51-9
化学式
C10H9BrO4
mdl
MFCD27949767
分子量
273.083
InChiKey
ZPKLKLLENLTZEX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    15
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    63.6
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-(2-乙酰基-4-溴苯氧基)乙酸sodium acetate乙酸酐 作用下, 以99.4%的产率得到5-溴-3-甲基苯并呋喃
    参考文献:
    名称:
    Preparation of 2-, 3-, 4- and 7-(2-alkylcarbamoyl-1-alkylvinyl)benzo[b]furans and their BLT1and/or BLT2inhibitory activities
    摘要:
    设计了几种2-烷基氨基甲酰基-1-烷基乙烯基苯并[b]呋喃,旨在寻找选择性的白三烯B4(LTB4)受体拮抗剂。合成了在3-位具有取代基的2-(2-烷基氨基甲酰基-1-烷基乙烯基)苯并[b]呋喃、在3-位具有取代基的4-(2-烷基氨基甲酰基-1-甲基乙烯基)苯并[b]呋喃、7-(2-烷基氨基甲酰基-1-甲基乙烯基)苯并[b]呋喃和3-(2-烷基氨基甲酰基-1-烷基乙烯基)苯并[b]呋喃,并评估了它们对LTB4受体(BLT1和BLT2)的抑制活性。(E)-3-氨基-4-[2-[2-(3,4-二甲氧基苯基)乙基氨基甲酰基]-1-甲基乙烯基]苯并[b]呋喃((E)-17c)显示出对BLT2具有强效且选择性的抑制活性。另一方面,(E)-7-(2-二乙基氨基甲酰基-1-甲基乙烯基)苯并[b]呋喃((E)-27a)对BLT1和BLT2均显示出强效的抑制活性。
    DOI:
    10.1039/b710935k
  • 作为产物:
    参考文献:
    名称:
    Preparation of 2-, 3-, 4- and 7-(2-alkylcarbamoyl-1-alkylvinyl)benzo[b]furans and their BLT1and/or BLT2inhibitory activities
    摘要:
    设计了几种2-烷基氨基甲酰基-1-烷基乙烯基苯并[b]呋喃,旨在寻找选择性的白三烯B4(LTB4)受体拮抗剂。合成了在3-位具有取代基的2-(2-烷基氨基甲酰基-1-烷基乙烯基)苯并[b]呋喃、在3-位具有取代基的4-(2-烷基氨基甲酰基-1-甲基乙烯基)苯并[b]呋喃、7-(2-烷基氨基甲酰基-1-甲基乙烯基)苯并[b]呋喃和3-(2-烷基氨基甲酰基-1-烷基乙烯基)苯并[b]呋喃,并评估了它们对LTB4受体(BLT1和BLT2)的抑制活性。(E)-3-氨基-4-[2-[2-(3,4-二甲氧基苯基)乙基氨基甲酰基]-1-甲基乙烯基]苯并[b]呋喃((E)-17c)显示出对BLT2具有强效且选择性的抑制活性。另一方面,(E)-7-(2-二乙基氨基甲酰基-1-甲基乙烯基)苯并[b]呋喃((E)-27a)对BLT1和BLT2均显示出强效的抑制活性。
    DOI:
    10.1039/b710935k
点击查看最新优质反应信息

文献信息

  • [EN] TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS<br/>[FR] TRIAZOLONES UTILISÉES COMME INHIBITEURS D'ACIDES GRAS SYNTHASE
    申请人:GLAXOSMITHKLINE LLC
    公开号:WO2011103546A1
    公开(公告)日:2011-08-25
    This invention relates to the use of triazolone derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones in the treatment of cancer.
    这项发明涉及三唑酮衍生物在调节脂肪酸合成酶(FAS)的活性或功能,特别是抑制其活性或功能方面的用途。适当地,本发明涉及三唑酮在癌症治疗中的应用。
  • AMINO ALCOHOL DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USE OF THESE
    申请人:Kissei Pharmaceutical Co., Ltd.
    公开号:EP1679304A1
    公开(公告)日:2006-07-12
    The present invention provides compounds represented by general formula (I): a prodrug thereof, or pharmaceutical acceptable salts thereof, wherein R1 is hydrogen or lower alkyl; each of R2 and R3 is independently hydrogen or lower alkyl; each of R4, R5 and R6 is independently hydrogen, halogen, lower alkyl or lower alkoxy; R7 is hydrogen or lower alkyl; R8 is hydrogen, halogen, lower alkyl, lower alkoxy, etc; R9 is -COR10, -A1-COR10, -O-A2-COR10, etc; Ar is optionally substituted phenyl or heteroaryl; and A is a bond, -OCH2-, etc, which exhibit potent and selective β3-adrenoceptor stimulating activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof.
    本发明提供了由通式(I)表示的化合物: 其前药,或其药用可接受的盐,其中R1是氢或较低的烷基;R2和R3中的每一个独立地是氢或较低的烷基;R4、R5和R6中的每一个独立地是氢、卤素、较低的烷基或较低的烷氧基;R7是氢或较低的烷基;R8是氢、卤素、较低的烷基、较低的烷氧基等;R9是-COR10、-A1-COR10、-O-A2-COR10等;Ar是可选择地取代的苯基或杂环芳基;A是键,-OCH2-等,具有强效和选择性的β3-肾上腺素受体刺激活性。本发明还提供了含有所述化合物的药物组合物,以及其用途。
  • Preparation of 2-, 3-, 4- and 7-(2-alkylcarbamoyl-1-alkylvinyl)benzo[b]furans and their BLT<sub>1</sub>and/or BLT<sub>2</sub>inhibitory activities
    作者:Kumiko Ando、Yoko Kawamura、Yukiko Akai、Jun-ichi Kunitomo、Takehiko Yokomizo、Masayuki Yamashita、Shunsaku Ohta、Takahiro Ohishi、Yoshitaka Ohishi
    DOI:10.1039/b710935k
    日期:——
    Several 2-alkylcarbamoyl-1-alkylvinylbenzo[b]furans were designed to find a selective leukotriene B4 (LTB4) receptor antagonist. 2-(2-Alkylcarbamoyl-1-alkylvinyl)benzo[b]furans having a substituent group at the 3-position, 4-(2-alkylcarbamoyl-1-methylvinyl)benzo[b]furans having a substituent group at the 3-position, and 7-(2-alkylcarbamoyl-1-methylvinyl)benzo[b]furans and 3-(2-alkylcarbamoyl-1-alkylvinyl)benzo[b]furans were prepared and evaluated for LTB4receptor (BLT1 and BLT2) inhibitory activities. (E)-3-Amino-4-[2-[2-(3,4-dimethoxyphenyl)ethylcarbamoyl]-1-methylvinyl]benzo[b]furan ((E)-17c) showed potent and selective inhibitory activity for BLT2. On the other hand, (E)-7-(2-diethylcarbamoyl-1-methylvinyl)benzo[b]furan ((E)-27a) showed potent inhibitory activity for both BLT1 and BLT2.
    设计了几种2-烷基氨基甲酰基-1-烷基乙烯基苯并[b]呋喃,旨在寻找选择性的白三烯B4(LTB4)受体拮抗剂。合成了在3-位具有取代基的2-(2-烷基氨基甲酰基-1-烷基乙烯基)苯并[b]呋喃、在3-位具有取代基的4-(2-烷基氨基甲酰基-1-甲基乙烯基)苯并[b]呋喃、7-(2-烷基氨基甲酰基-1-甲基乙烯基)苯并[b]呋喃和3-(2-烷基氨基甲酰基-1-烷基乙烯基)苯并[b]呋喃,并评估了它们对LTB4受体(BLT1和BLT2)的抑制活性。(E)-3-氨基-4-[2-[2-(3,4-二甲氧基苯基)乙基氨基甲酰基]-1-甲基乙烯基]苯并[b]呋喃((E)-17c)显示出对BLT2具有强效且选择性的抑制活性。另一方面,(E)-7-(2-二乙基氨基甲酰基-1-甲基乙烯基)苯并[b]呋喃((E)-27a)对BLT1和BLT2均显示出强效的抑制活性。
  • Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof
    申请人:Kobayashi Junichi
    公开号:US20060128807A1
    公开(公告)日:2006-06-15
    The present invention provides compounds represented by general formula (I): or pharmaceutical acceptable salts thereof, wherein R 1 and R 2 are each hydrogen or lower alkyl; R 3 , R 4 , R 5 and R 6 are each hydrogen, halogen, lower alkyl or lower alkoxy; R 7 and R 8 are each hydrogen, halogen, lower alkyl, halo-lower alkyl, lower alkoxy, cycloalkyl, aryl, heteroaryl, cyano, a hydroxyl group, lower acyl, carboxy or the like; R 9 is —C(O)—R 10 , -A 1 -C(O)—R 10 , —O-A 2 -C(O)—R 10 or a tetrazol-5-yl group, which exhibit potent and selective β3-adrenoceptor stimulating activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof.
    本发明提供一般式(I)所表示的化合物或其药学上可接受的盐,其中R1和R2均为氢或较低的烷基;R3、R4、R5和R6均为氢、卤素、较低的烷基或较低的烷氧基;R7和R8均为氢、卤素、较低的烷基、卤代较低的烷基、较低的烷氧基、环烷基、芳基、杂芳基、氰基、羟基、较低的酰基、羧基或类似物;R9为—C(O)—R10、-A1-C(O)—R10、—O-A2-C(O)—R10或四唑-5-基团,其表现出强效和选择性的β3肾上腺素能受体刺激活性。本发明还提供含有该化合物的药物组合物及其用途。
  • Amino alcohol derivatives, medicinal composition containing the same, and use of these
    申请人:Kobayashi Junichi
    公开号:US20070078184A1
    公开(公告)日:2007-04-05
    The present invention provides compounds represented by general formula (I): a prodrug thereof, or pharmaceutical acceptable salts thereof, wherein R 1 is hydrogen or lower alkyl; each of R2 and R3 is independently hydrogen or lower alkyl; each of R 4 , R 5 and R 6 is independently hydrogen, halogen, lower alkyl or lower alkoxy; R 7 is hydrogen or lower alkyl; R 8 is hydrogen, halogen, lower alkyl, lower alkoxy, etc; R 9 is —COR 10 , -A 1 -COR 10 , —O-A 2 -COR 10 , etc; Ar is optionally substituted phenyl or heteroaryl; and A is a bond, —OCH 2 —, etc, which exhibit potent and selective β3-adrenoceptor stimulating activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof.
    本发明提供了由通式(I)表示的化合物:其前体,或其药学上可接受的盐,其中R1是氢或较低的烷基;R2和R3各自独立地是氢或较低的烷基;R4,R5和R6各自独立地是氢,卤素,较低的烷基或较低的烷氧基;R7是氢或较低的烷基;R8是氢,卤素,较低的烷基,较低的烷氧基等;R9是-COR10,-A1-COR10,-O-A2-COR10等;Ar是可选取代的苯基或杂环芳基;A是键,-OCH2-等,这些化合物表现出潜在和选择性的β3-肾上腺素能受体刺激活性。本发明还提供了含有上述化合物的药物组合物及其用途。
查看更多